Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis, Immunexpress Partner to Develop Sepsis Test

NEW YORK (GenomeWeb) – Biocartis announced today that it has signed an agreement with Immunexpress to accelerate development and commercialization of Immunexpress' Septicyte test for use on Biocartis' Idylla platform.

Immunexpress is currently developing tests based on biomarker signatures that gauge the response of a patient's immune system to infections. Immunexpress' Septicyte Lab, the firm's initial test, recently received 510(k) clearance from the US Food and Drug Administration for use on a manual PCR instrument. The test uses RT-qPCR to quickly differentiate sepsis from systemic inflammatory response syndrome in extremely ill patients within hours of admittance to the intensive care unit.

"[The SeptiCyte] test will definitely benefit from the unique features of our Idylla system, which allows results to be generated in a timeframe that supports the time-critical decision-making required in the management of sepsis patients," Biocartis CEO Herman Verrelst said in a statement.

The two companies will codevelop the Septicyte Idylla test. Immunexpress will lead commercialization efforts, which will initially focus on the US and Europe. Financial and other terms of the agreement were not disclosed.

Earlier this month, Biocartis signed a deal with Amgen to develop CDx biomarker tests on the Idylla platform.